Filing Flows › Aligos Therapeutics (ALGS) › Q4 2024
Aligos Therapeutics (ALGS) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 10, 2025
Aligos Therapeutics (ALGS) reported revenue of $606K for the fourth quarter 2024 (Q4 2024), -10% from a year earlier and -52% from the quarter before.
Aligos Therapeutics, Q4 2024: revenue $606K (-10% year over year), net loss $82.2M, operating cash flow −$18.4M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $606K | -52% | -10% |
| Operating profit | −$20.6M | — | — |
| Net earnings | −$82.2M | — | — |
| Operating cash flow | −$18.4M | — | — |
What changed
Revenue was $606K in Q4 2024, down 10% year over year and down 52% from the previous quarter.
Operating costs exceeded revenue by $20.6M, an operating margin of -3393.2%. Total costs fell 21% while revenue fell 10%. The quarter ended with a net loss of $82.2M, wider than the previous quarter's $19.3M loss. Net interest and other expense of $61.6M was the main reason.
Operating cash flow was −$18.4M. Non-cash charges added back $241K of depreciation and $1.7M of share-based compensation. Working capital and other items added $61.8M.
Questions
What was Aligos Therapeutics' revenue in the fourth quarter 2024?
Aligos Therapeutics (ALGS) reported revenue of $606K for the fourth quarter 2024 (Q4 2024), -10% from a year earlier and -52% from the quarter before.